Biochemistry and physiology of anabolic androgenic steroids doping

Mini-Reviews in Medicinal Chemistry

Volumn 11, Issue 5, 2011, Pages 362-373

  Lippi, G ^a   Franchini, M ^a   Banfi, G ^b  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Anabolic androgenic steroids; Doping; Sports; Testosterone

Indexed keywords

ANABOLIC AGENT; BOLASTERONE; BOLDENONE; CALUSTERONE; CLOSTEBOL; DROSTANOLONE; ETHYLESTRENOL; FLUOXYMESTERONE; FORMEBOLONE; FURAZABOL; MADOL; MESTANOLONE; MESTEROLONE; METANDIENONE; METENOLONE; METHANDRIOL; METHYLTESTOSTERONE; NANDROLONE; NORBOLETONE; NORCLOSTEBOL; NORETHANDROLONE; OXANDROLONE; OXYMESTERONE; OXYMETHOLONE; QUINBOLONE; STANOZOLOL; STENBOLONE; TESTOSTERONE; TETRAHYDROGESTRINONE; TRENBOLONE; UNCLASSIFIED DRUG;

ATHLETIC PERFORMANCE; BIOCHEMISTRY; DOPING; DRUG ABUSE; DRUG EFFECT; HUMAN; REVIEW; SPORT;

ANABOLIC AGENTS; ANIMALS; DOPING IN SPORTS; HUMANS; MOLECULAR STRUCTURE; MUSCLE STRENGTH; STEROIDS;

EID: 79955644500     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955711795445952     Document Type: Review

References (66)

1. Roy, P.; Alevizaki, M.; Huhtaniemi, I. In vitro bioassays for androgens and their diagnostic applications. Human Reprod., 2008, 14, 73-82.
2. Kicman, A.T. Pharmacology of anabolic steroids. Br. J. Pharmacol., 2008, 154, 502-521.
3. Kicman, A.T. Biochemical and physiological aspects of endogenous androgens. Handb. Exp. Pharmacol., 2010, 195, 26-64.
4. Schulze, J.J.; Lundmark, J.; Garle, M.; Skilving, I.; Ekström, L.; Rane, A. Doping test results dependent on genotype of uridine uridine diphospho-glucuronosyl transferase 2B17, the major enzyme for testosterone glucuronidation. J. Clin. Endocrinol. Metab., 2008, 93, 2500-2506.
5. Schulze, J.J.; Lundmark, J.; Garle, M.; Ekström, L.; Sottas, P.E.; Rane, A. Substantial advantage of a combined Bayesian and genotyping approach in testosterone doping tests. Steroids, 2009, 74, 365-8.
6. Dehennin, L. Secretion by the human testis of epitestosterone, with its sulfoconjugate and precursor androgen 5-androstene-3 beta,17 alpha-diol. J. Steroid Biochem. Mol. Biol., 1993, 44, 171-177.
7. Weusten, J.J.; Legemaat, G.; van der Wouw, M.P.; Smals, A.G.; Kloppenborg, P.W.; Benraad, T. The mechanism of the synthesis of 16-androstenes in human testicular homogenates. J. Steroid. Biochem., 1989, 32, 689-694.
8. Schänzer, W. Metabolism of anabolic androgenic steroids. Clin. Chem., 1996, 42, 1001-1020.
9. Parr, M.K.; Flenker, U.; Schänzer, W. Sports-related issues and biochemistry of natural and synthetic anabolic substances. Endocrinol. Metab. Clin. N. Amer., 2010, 39, 45-57.
10. Thevis, M.; Schänzer, W. Synthetic anabolic agents: steroids and nonsteroidal selective androgen receptor modulators. Handb. Exp. Pharmacol., 2010, 195, 99-126.
11. Thevis, M.; Thomas, A.; Kohler, M.; Beuck, S.; Schänzer. W. Emerging drugs: mechanism of action, mass spectrometry and doping control analysis. J. Mass. Spectrom., 2009, 44, 442-460.
12. Schänzer, W.; Opfermann, G.; Donike, M. Metabolism of stanozolol: identification and synthesis of urinary metabolites. J. Steroid. Biochem., 1990, 36, 153-174.
13. Reznik, Y.; Herrou, M.; Dehennin, L.; Lemaire, M.; Leymarie, P. Rising plasma levels of 19-nortestosterone throughout pregnancy: determination by radioimmunoassay and validation by gas chromatography-mass spectrometry. J. Clin. Endocrinol. Metab., 1987, 64, 1086-1088.
14. Le Bizec, B.; Monteau, F.; Gaudin, I.; Andre, F. Evidence for the presence of endogenous 19-norandrosterone in human urine. J. Chromatogr. B Biomed. Sci. Appl., 1999, 723, 157-172.
15. Robinson, N.; Taroni, F.; Saugy, M.; Ayotte, C.; Mangin, P.; Dvorak. J. Detection of nandrolone metabolites in urine after a football game in professional and amateur players: a Bayesian comparison. Forensic. Sci. Int. 2001, 122, 130-135.
16. Friedel, A.; Geyer, H.; Kamber, M.; Laudenbach-Leschowsky, U.; Schänzer, W.; Thevis, M.; Vollmer, G.; Zierau, O.; Diel, P. Tetrahydrogestrinone is a potent but unselective binding steroid and affects glucocorticoid signalling in the liver. Toxicol. Lett. 2006, 164, 16-23.
17. Catlin, D.H.; Sekera, M.H.; Ahrens, B.D.; Starcevic, B.; Chang, Y.C.; Hatton, C.K. Tetrahydrogestrinone: discovery, synthesis, and detection in urine. Rapid. Commun. Mass. Spectrom. 2004, 18, 1245-1249.
18. Brower, K.J. Anabolic steroid abuse and dependence. Curr. Psychiatry. Rep. 2002, 4, 377-387.
19. Franke, W.W.; Berendonk, B. Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government. Clin. Chem. 1997, 43, 1262-1279.
20. Wade, N. Anabolic steroids: doctors denounce them but athletes aren't listening. Science, 1972, 176, 1399-1403.
21. Bahrke, M.S.; Yesalis, C.E. Abuse of anabolic androgenic steroids and related substances in sport and exercise. Curr. Opin. Pharmacol., 2004, 4, 614-620.
22. Yesalis, C.E.; Courson, S.P.; Wright, J. History of anabolic steroid use. In: Yesalis CE, ed. Anabolic steroids in sports and exercise. Champaign, IL: Human Kinetics; 1993; pp. 36-40.
23. World Anti-Doping Agtency. 2006 Adverse analytical findings reported by accredited laboratories. Available from: http://www.wada-ama.org/rtecontent/document/LABSTATS_2006. pdf.
24. Buckley, W.E.; Yesalis, C.E. III; Friedl, K.E.; Anderson, W.A.; Streit, A.L.; Wright J.E. Estimated prevalence of anabolic steroid use among male high school seniors. JAMA, 1988, 260, 3441-3445.
25. Kanayama, G.; Pope, H.G. Jr; Hudson, J.I. 'Body image' drugs: a growing psychosomatic problem. Psychother. Psychosom., 2001, 70, 61-65.
26. Parkinson, A.B.; Evans, N.A. Anabolic androgenic steroids: a survey of 500 users. Med Sci Sports Exerc 2006, 38, 644-651.
27. Kanayama, G.; Hudson, J.I.; Pope, H.G. Demographic and psychiatric features of men with anabolic androgenic steroid dependence: a comparative study. Drug Alcohol Depend., 2009, 102, 130-137.
28. Leit, R.A.; Pope, H.G. Jr; Gray, J.J. Cultural expectations of muscularity in men: the evolution of Playgirl centerfolds. Int. J. Eat. Disord. 2001, 29, 90-93.
29. Yesalis, C.E.; Barsukiewicz, C.K.; Kopstein, A.N.; Bahrke, M.S. Trends in anabolic-androgenic steroid use among adolescents. Arch. Pediatr. Adolesc. Med. 1997, 151, 1197-1206.
30. rd, C.E.; Friedl, K.E.; Anderson, W.A.; Streit, A.L.; Wright, J.E. Estimated prevalence of anabolic steroid use among male high school seniors. JAMA, 1988, 260, 3441-3445.
31. Yesalis, C.E.; Bahrke, M.S.; Kopstein, A.N.; Barsukiewicz, C.K. Incidence of anabolic steroids use: a discussion of methodological issues. In Anabolic Steroids in Sport and Exercise, Second Edition. Edited by Yesalis CE. Champaign: Human Kinetics; 2000; pp. 73-115.
32. Yesalis, C.E.; Kennedy, N.J.; Kopstein, A.N.; Bahrke, M.S. Anabolic-androgenic steroid use in the United States. JAMA, 1993, 270, 1217-1221.
33. Van Amsterdam, J.; Opperhuizen, A.; Hartgens, F. Adverse health effects of anabolic-androgenic steroids. Regul. Toxicol. Pharmacol., 2010, 57, 117-123.
34. Williamson, D.J. Anabolic steroid use among students at a British college of technology. Br. J. Sports. Med., 1993, 27, 200-201.
35. Nilsson, S. Androgenic-anabolic steroid use among male adolescents in Falkenberg. Eur. J. Clin. Pharmacol. 1995, 48, 9-11.
36. Nilsson, S.; Baigi, A.; Marklund, B.; Fridlund, B. The prevalence of the use of androgenic-anabolic steroids by adolescents in a county of Sweden. Eur. J. Public. Health., 2001, 11, 195-197.
37. Thiblin, I.; Petersson, A. Pharmacoepidemiology of anabolicandrogenic steroids: a review. Fundam. Clin. Pharmacol., 2005, 19, 27-44.
38. Bahrke, M.S.; Yesalis, C.E.; Kopstein, A.N.; Stephens, J.A., Risk factors associated with anabolic-androgenic steroid use among adolescents. Sports Med., 2000, 29, 397-405.
39. DuRant, R.H.; Escobedo, L.G.; Heath, G.W. Anabolic-steroid use, strength training, and multiple drug use among adolescents in the United States. Pediatrics., 1995, 96, 23-28.
40. Cohen, J.; Collins, R.; Darkes, J.; Gwartney, D. A league of their own: demographics, motivations and patterns of use of 1,955 male adult non-medial anabolic steroid users in the United States. J. Intern. Soc. Sports. Nutr., 2007, 4, 12-28.
41. Hall, R.C.; Hall, R.C. Abuse of supraphysiologic doses of anabolic steroids. South Med. J., 2005, 98, 550-555.
42. Choong, K.; Lakshman, K.M.; Bhasin, S. The physiological and pharmacological basis for the ergogenic effects of androgens in elite sports. Asian J. Androl., 2008, 10, 351-363.
43. Hartgens, F.; Kuipers, H. Effects of androgenic-anabolic steroids in athletes. Sports Med., 2004, 34, 513-554.
44. Kadi, F. Cellular and molecular mechanisms responsible for the action of testosterone on human skeletal muscle. A basis for illegal performance enhancement. Br. J. Pharmacol., 2008, 154, 522-528.
45. Handelsman, D.J. Indirect androgen doping by oestrogen blockade in sports. Br. J. Pharmacol., 2008, 154, 598-605.
46. Evans, N.A. Current concepts in anabolic-androgenic steroids. Am. J. Sports. Med., 2004, 32, 534-542.
47. American Academy of Orthopaedic Surgeons. Position Statement. Anabolic Steroids to Enhance Athletic Performance. Available at: http://www.aaos.org/about/papers/position/1102.asp. Last Accessed: 23 September 2010.
48. Hervey, G.R.; Hutchinson, I.; Knibbs, A.V.; Burkinshaw, L.; Jones, P.R.; Norgan, N.G.; Levell, M.J. Anabolic effects of methandienone in men undergoing athletic training. Lancet, 1976, 2, 699-702.
49. Hervey, G.R.; Knibbs, A.V.; Burkinshaw, L.; Morgan, D.B.; Jones, P.R.; Chettle, D.R.; Vartsky, D. Effects of methandienone on the performance and body composition of men undergoing athletic training. Clin. Sci., 1981, 60, 457-461.
50. Bhasin, S.; Storer, T.W.; Berman, N.; Callegari, C.; Clevenger, B.; Phillips, J.; Bunnell, T.J.; Tricker, R.; Shirazi, A.; Casaburi, R. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N. Engl. J. Med., 1996, 335, 1-7.
51. Bhasin, S.; Woodhouse, L.; Casaburi, R.; Singh, A.B.; Bhasin, D.; Berman, N.; Chen, X.; Yarasheski, K.E.; Magliano, L.; Dzekov, C.; Dzekov, J.; Bross, R.; Phillips, J.; Sinha-Hikim, I.; Shen, R.; Storer, T.W. Testosterone dose-response relationships in healthy young men. Am. J. Physiol. Endocrinol. Metab., 2001, 281, E1172-E1181.
52. Sinha-Hikim, I.; Artaza, J.; Woodhouse, L.; Gonzalez-Cadavid, N.; Singh, A.B.; Lee, M.I.; Storer, T.W.; Casaburi, R.; Shen, R.; Bhasin, S. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am. J. Physiol. Endocrinol. Metab., 2002, 283, E154-E164.
53. Storer, T.W.; Magliano, L.; Woodhouse, L.; Lee, M.L.; Dzekov, C.; Dzekov, J.; Casaburi, R.; Bhasin, S. Testosterone dosedependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J. Clin. Endocrinol. Metab., 2003, 88, 1478-1485.
54. van Marken Lichtenbelt, W.D.; Hartgens, F.; Vollaard, N.B.; Ebbing, S.; Kuipers, H. Bodybuilders' body composition: effect of nandrolone decanoate. Med. Sci. Sports Exerc., 2004, 36, 484-489.
55. Johnson, L.C.; O'Shea, J.P. Anabolic steroid: effects on strength development. Science, 1969, 164, 957-959.
56. Elashoff, J.D.; Jacknow, A.D.; Shain, S.G.; Braunstein, G.D. Effects of anabolic-androgenic steroids on muscular strength. Ann. Intern. Med., 1991, 115, 387-393.
57. Kuhn, C.M. Anabolic steroids. Recent Prog. Horm. Res., 2002, 57, 411-434.
58. Rogerson, S.; Weatherby, R.P.; Deakin, G.B.; Meir, R.A.; Coutts, R.A.; Zhou, S.; Marshall-Gradisnik, S.M. The effect of short-term use of testosterone enanthate on muscular strength and power in healthy young men. J. Strength Cond. Res., 2007, 21, 354-361.
59. George, A.J. Androgenic anabolic steroids. In: Mottram DR, editor. Drugs in sport. 3rd. London: Routledge; 2003. pp. 138-88.
60. Shahani, S.; Braga-Basaria, M.; Maggio, M.; Basaria, S. Androgens and erythropoiesis: past and present. J. Endocrinol. Invest., 2009, 32, 704-716.
61. Van Zyl, C.G.; Noakes, T.D.; Lambert, M.I. Anabolic-androgenic steroid increases running endurance in rats. Med. Sci. Sports. Exerc., 1995, 27, 1385-1389.
62. Liang, M.T.; Paulson, D.J.; Kopp, S.J.; Glonek, T.; Meneses, P.; Gierke, L.W.; Schwartz, F.N. Effects of anabolic steroids and endurance exercise on cardiac performance. Int. J. Sports. Med., 1993, 14, 324-329.
63. Gayan-Ramirez, G.; Rollier, H.; Vanderhoydonc, F.; Verhoeven, G.; Gosselink, R.; Decramer, M. Nandrolone decanoate does not enhance training effects but increases IGF-I mRNA in rat diaphragm. J. Appl. Physiol., 2000, 88, 26-34.
64. Georgieva, K.N.; Boyadjiev, N.P. Effects of nandrolone decanoate on VO2max, running economy, and endurance in rats. Med. Sci. Sports. Exerc., 2004, 36, 1336-1341.
65. Tamaki, T.; Uchiyama, S.; Uchiyama, Y.; Akatsuka, A.; Roy, R.R.; Edgerton, V.R. Anabolic steroids increase exercise tolerance. Am. J. Physiol. Endocrinol. Metab., 2001, 280, E973-E981.
66. Baume, N.; Schumacher, Y.O.; Sottas, P.E.; Bagutti, C.; Cauderay, M.; Mangin, P.; Saugy, M. Effect of multiple oral doses of androgenic anabolic steroids on endurance performance and serum indices of physical stress in healthy male subjects. Eur. J. Appl. Physiol., 2006, 98, 329-340.